Lexaria Bioscience Corp. LXRP Archives - Page 6 of 27

FridaySep 13, 2019 2:36 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Developing Novel Nicotine Ingestion Method as Smoking Alternative

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), an innovative biotechnology company, has set its sights on using its proprietary drug delivery technology to provide an alternative method of nicotine ingestion that is safer than smoking. An article further discussing the company reads, “The technology, known as DehydraTECH(TM), is a patented, cost-effective delivery mechanism that has been shown to improve the ingestibility of cannabinoids, vitamins, nonsteroid anti-inflammatory drugs (NSAIDs) and nicotine. Now, Lexaria has partnered with one of the world’s largest tobacco firms to develop new, reduced-risk, oral nicotine products using the technology (http://ibn.fm/pddAe). . . . The deal funds Lexaria’s R&D program…

FridaySep 06, 2019 3:24 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Reports Positive Findings from Master Collaborative Research Agreement

Biotechnology company and global drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) recently announced the successful completion of its master collaborative research agreement with the National Research Council of Canada (“NRC”) focused on technical aspects of DehydraTECH(TM)’s drug-delivery processes (http://ibn.fm/R94q9). An article further discussing the company reads, “Lexaria also noted that the National Research Council of Canada study discovered the remarkable stability of DehydraTECH technology, even under highly acidic conditions. ‘Other formulation technologies by third parties that have not been tested for pH stability cannot be relied upon to deliver stable quantities of the API in question…

WednesdaySep 04, 2019 11:00 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Rolls Out Online Sales of Discrete Powdered Formulation of CBD-Rich Hemp Oil

Lexaria Bioscience is an innovator in the field of bioavailable lipophilic active compounds, and it is working to make consumption of certain products through oral ingestion a viable alternative to inhalation A particular focus of the company’s technology is to ensure that cannabinoids can enter the blood stream at speeds comparable to smoking and can be used in a discrete manner Cannabis-infused beverage sales are expected to surpass $1.4 billion by 2024, marking a nearly 15-fold increase over 2018 levels Drug bio-delivery technology innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has launched online commercial delivery of the cannabis industry’s…

TuesdayAug 27, 2019 9:55 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Receives DehydraTECH Patent for Pharmaceutical Applications of Cannabinoids to Treat Certain Conditions

Biotechnology company and global drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announced its receipt of a new patent granted in Australia: #2016367037 / Grant Date August 15, 2019 - “Stable ready-to-drink beverage compositions comprising lipophilic active agents.” According to the update, this increases Lexaria’s portfolio to 16 awarded patents protecting its DehydraTECH(TM) drug delivery platform, with eight in the USA and eight in Australia. The new Australian patent, together with Australian Patent #2016367036 announced on August 15, 2019, are the first granted in Lexaria’s second and third patent families that differ from the company’s original…

ThursdayAug 22, 2019 10:41 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Commercial Launch of ChrgD+

Biotechnology company and global drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced the commercial launch of ChrgD+, the industry’s most advanced water-soluble multi-spectrum hemp oil in a powdered format and empowered with DehydraTECH(TM) for fast, effective delivery. ChrgD+ is available online, now for sale to US consumers at ChrgD.life. Lexaria’s technology delivers patented processes within every ChrgD+ serving to improve the consumer experience of hemp oil with CBD. ChrgD+ is formulated with the highest quality multi-spectrum hemp oil ingredients and does NOT use CBD isolates that deprive consumers of the synergistic benefits of multi-spectrum oils. In…

TuesdayAug 20, 2019 2:30 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Joint Manufacturing Partnership Opens Door to Widespread Distribution

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a biotechnology company and drug-delivery platform innovator, is increasing the reach of its revolutionary DehydraTECH(TM) technology that enables the rapid onset of ingested cannabis. An article discussing the company reads, “DehydraTECH is a drug-delivery technology that gets ingested active pharmaceutical ingredient (API) molecules to the bloodstream faster than other methods. Under a new agreement announced July 24, the company will expand DehydraTECH’s reach by allowing Hill Street Beverage Company Inc. (TSX.V: BEER), a manufacturer of alcohol-free and cannabis-infused beer, wine and adult-format beverages, to produce commercial products in partnership with Lexaria under a new…

TuesdayAug 20, 2019 11:38 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Drug-Delivery Platform Could Help Smokers Stub Cigarettes

Lexaria recently announced its entry into a partnership with a tobacco giant to fund the research and development of oral nicotine delivery solutions The company received a cannabis R&D license from Health Canada LXRP also announced its receipt of four new patents and its launch of ChrgD+ Many consumers don’t realize that they don’t need to smoke to partake of nicotine. In fact, new advancements are providing an alternative to the risks associated with smoking, which were first officially revealed by a damning surgeon general report in 1963 linking smoking to lung cancer, emphysema and heart disease. Case in point,…

MondayAug 19, 2019 1:05 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) R&D Finds Lack of Adverse Chemical Byproducts in Manufacture of Drug Delivery Compositions

Lexaria Bioscience is involved in the research and improvement of its trademarked DehydraTECH technology, which enhances the bioavailability of some legal drug substances used by consumers The technology provides a rapid-on, rapid-off effect that may be effectively used in cannabis-infused edibles and beverages as an alternative to mind-altering substances such as alcohol and cannabis New research has boosted Lexaria’s hopes, with findings that show no adverse NME chemical compositions were formed in several rounds of in-depth testing The company recently formed a collaboration with Hill Street Beverage Company to make cannabis-infused alternatives to alcoholic beverages By 2024, cannabis-infused beverage sales…

ThursdayAug 15, 2019 10:15 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Receives Four New Patents, Increasing Total Granted to 15

Biotechnology company and global drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced the granting of four of its pending patent applications via its wholly-owned subsidiary Poviva Corp. According to the update, the new patents cover delivery of cannabinoids such as THC and CBD, NSAIDs such as ibuprofen, nicotine, and vitamins. With issuance of these four patents, Lexaria’s total patents granted has increased to 15, with eight in the US and seven in Australia, and the company has roughly 60 patent applications pending throughout the world. Lexaria is one of the most patent-rich firms in the Western…

WednesdayAug 14, 2019 12:43 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Appoints Consumer Packaged Goods Veteran to Board of Directors

Biotechnology company and global drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced the appointment of Brian Quigley to its board of directors. Quigley most recently spent 16 years at Altria Group, seven of which were spent as president and CEO for U.S. Smokeless Tobacco and Nu-Mark, Altria's innovation company, during the time that the existing Lexaria and Altria business relationship was negotiated. Quigley is a 20-year Consumer Packaged Goods veteran with a background of managing complex regulatory environments including for novel and innovative nicotine products, and holds additional deep experience with operations and marketing. “Lexaria continues…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXRP